CLLS

$3.18+$0.24 (+8.16%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$296.1M

101M shares

52-week range

$2.35 – $5.48

27% from low

Exchange

NASDAQ

ADRC

Change$-9.41

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$58M	-24.5%	$-0.89	$-1.22–$-0.72	—	6
2027	$117M	+99.7%	$-0.67	$-0.99–$-0.45	—	5
2028	$52M	-55.1%	$-1.32	$-2.59–$-0.35	—	2
2029	$87M	+65.5%	$-1.13	$-2.21–$-0.30	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.26	$-0.22	+16.3%
2026-05-11	$-0.26	$-0.18	+30.3%
2026-03-19	$-0.20	$-0.26	-27.9%
2025-11-07	$-0.10	$0.01	+110.0%
2025-08-04	$-0.10	$-0.24	-140.0%
2025-05-12	$-0.19	$-0.18	+5.3%
2025-03-13	$0.06	$-0.16	-366.7%
2024-11-04	$-0.20

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CLLSCellectis S.A.	$3.18	+7.25%	$319M	—
ACIUAC Immune S.A.	$2.57	-1.91%	$262M	—
ALDXAldeyra The	$1.44	-5.26%	$87M	—
AMRNAmarin Corporation plc	$14.15	+0.64%	$293M	—
ANROAlto Neuroscience, Inc.	$32.30	+10.69%

Cellectis S.A. American Depositary Shares

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

www.cellectis.com

Employees: 229
IPO / List date: Mar 25, 2015

Held by traders on TradeandTell

No one on the platform currently holds CLLS.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in CLLS as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded CLLS yet.

$CLLS chatter on StockTwits

Damian@ZephixBullish9h
$CLLS Vvs2
View on StockTwits ↗
Randy@rlkloehn2d
$CLLS Wells Fargo 21st Annual Healthcare Conference — September 8-10, 2026, Encore Boston Harbor Hotel, Everett (Boston, MA). Choulika, Kilcoyne (CMO) and Stril attend and hold investor meetings. No public presentation announced 2026 Baird's Global Healthcare Conference — September 15, 2026, New York City. Choulika and Stril give a presentation from 12:50 to 13:20 (Eastern Time), plus investor meetings.
View on StockTwits ↗
Randy@rlkloehnAug 6
$CLLS https://markets.businessinsider.com/news/stocks/cellectis-reports-financial-results-for-the-second-quarter-2026-1036422913?op=1
View on StockTwits ↗
TRB@TheRedBaron8888Aug 4
@rlkloehn It's been a long ride with $ALLO . Even more so with $CLLS. Let's hope for everyone's sake it all works out well.
View on StockTwits ↗
Randy@rlkloehnJul 31
$CLLS https://www.linkedin.com/posts/cellectis-to-report-second-quarter-financial-share-7488693137373118465-8-zD/?utm_source=share&utm_medium=member_ios&rcm=ACoAAF-Iu-0Br2vbs8MA5ZcTEtcSRu6s-HTVNwc
View on StockTwits ↗
kule@kule04Jul 21
$CLLS Why did this drop hard?
View on StockTwits ↗
Randy@rlkloehnJul 7
$CLLS Adrian Kilcoyne Chief Medical Officer of Cellectis, will participate in this summit in September. Thursday, September 17, 2026 Establish the benchmark for efficacy and safety in treatment by CAR-T Lessons learned from the design of a double CAR-T: why target CD20 and CD22. Presentation of preliminary data on eti-cel
View on StockTwits ↗
Randy@rlkloehnJul 4
$CLLS MEMORANDUM ORDER Granting-In-Part re50 MOTION to Stay Proceedings Pending Interference filed by Cellectis, Inc., Cellectis S.A. Signed by Judge Gregory B. Williams on 6/29/2026. (lnb) Case Stayed (lnb) On May 5, 2026, the Patent Trial and Appeal Board (PTAB) officially opened Interference No. 106,318, covering all patent claims in dispute. This procedure is intended to determine who was the first inventor of the invention concerned. Cellectis is referred to as Senior Party (presumed to have invented first) and Factor Bioscience as Junior Party. The court considers that a PTAB decision could: annul some or all of the patents invoked by Factor Bioscience; significantly reduce the remaining issues to be judged; or even render the trial unnecessary if Cellectis is recognized as the first inventor.
View on StockTwits ↗
Crazy K@PennyScamJun 25
$CLLS Results….
View on StockTwits ↗
jorge .miguel@focafoca99Jun 11
$CLLS shared final Phase 1 data showing 100% response rate for lasme‑cel and promising early results for eti‑cel at the EHA 2026 Congress.
View on StockTwits ↗
Open Outcrier@OpenOutcrierJun 10
$CLLS (+5.4% pre) Cellectis receives FDA RMAT designation for blood cancer therapy https://ooc.bz/l/104705
View on StockTwits ↗
Stocktwits News@StocktwitsNewsJun 9
CLLS Stock Rallies Over 24% After Hours — Here's Why $CLLS https://stocktwits.com/news/equity/markets/clls-stock-rallies-after-hours-heres-why/cZ0UqzWR7Rq
View on StockTwits ↗
Top Stock Alerts@topstockalertsJun 9
After Hours Top Gainers PT2 $CLLS $HKPD $HKIT $YYGH $CGTL
View on StockTwits ↗
NOTRELOAD AI@notreload_aiJun 9
$CLLS got FDA RMAT for lasme-cel, an off-the-shelf CAR-T therapy for hard-to-treat leukemia that may speed up patient access. https://notreload.xyz/xy/fda-grants-rmat-to-cellectis-lasme-cel-car-t-therapy/
View on StockTwits ↗
Stoxpo@StoxpoBullishJun 9
$CLLS up 13.31% Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL $CLLS $XBI
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.